# 1 Alpha7 nicotinic acetylcholine receptor agonist PHA 568487

## 2 dampens inflammation in PBMCs from patients with newly

# 3 discovered coronary artery disease.

- 4
- 5 Filip Mjörnstedt<sup>1</sup>, Rebecka Wilhelmsson<sup>1</sup> M. Sc., Marcus Ulleryd<sup>1</sup> PhD, Maria Hammarlund<sup>1</sup>
- 6 PhD, Göran Bergström<sup>2,3</sup>MD, PhD, Anders Gummesson<sup>2,4</sup> MD, PhD, Maria E Johansson<sup>1</sup>
- 7 PhD.
- <sup>8</sup> <sup>1</sup>Department of Physiology, Institute of Neuroscience and Physiology, and <sup>2</sup>Department of
- 9 Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, Gothenburg
- 10 University, Gothenburg, Sweden
- <sup>3</sup>Department of Clinical Physiology and <sup>4</sup> Department of Clinical Genetics and Genomics,
- 12 Sahlgrenska University Hospital, Västra Götalandsregionen, Gothenburg, Sweden.
- 13
- 14 **Word Count:** 997
- 15 Keywords: coronary artery disease, atherosclerosis, inflammation, alpha7 nicotinic
- 16 acetylcholine receptor.
- 17
- 18 Correspondence
- 19 Maria E. Johansson,
- 20 <u>maria.e.johansson@neuro.gu.se</u>
- 21 Department of Physiology
- 22 Institute of Neuroscience and Physiology
- 23 The Sahlgrenska Academy, University of Gothenburg,
- 24 Box 432, Gothenburg 405 30, Sweden

# 25 Abstract

26	<b>Background:</b> The alpha7 nicotinic acetylcholine receptor ( $\alpha$ 7nAChR) controls inflammation
27	in experimental models. The $\alpha$ 7nAChR is expressed in human peripheral blood mononuclear
28	cells (PBMCs) as well as in human atherosclerotic plaques, yet, its role in regulating
29	inflammation in patients with cardiovascular disease remains unknown. In this study we aim
30	to investigate whether stimulation of the $\alpha$ 7nAChR can dampen the immune response in
31	patients with newly discovered coronary artery disease (CAD).
32	Methods: Human peripheral blood mononuclear cells (PBMCs) extracted from patients with
33	verified CAD (n=38) and control participants with healthy vessels (n=38) were challenged in
34	vitro with lipopolysaccharide (LPS) in combination with $\alpha$ 7nAChR agonist PHA 568487.
35	Supernatants were analyzed for cytokines using multiplex immunoassay. The CAD group
36	was re-examined after 6 months.
37	<b>Results:</b> $\alpha$ 7nAChR stimulation decreased TNF- $\alpha$ in all groups, in control participants and in
38	CAD patients, both at the first visit as well as the follow-up visit after 6 months. The most
39	pronounced effect of $\alpha$ 7nAChR stimulation was seen in CAD patients at their first visit,
40	where 12 of 17 cytokines were decreased (TNF- $\alpha$ , IL-1 $\beta$ , IL-2, IL-4, IL-5, IL-7, IL-10, IL-
41	17A, GM-CSF, MCP-1, MIP-1β and IL12(p70)).
42	<b>Conclusions: S</b> timulation of $\alpha$ 7nAChR dampens the inflammatory response in human
43	PBMCs. This suggests that the anti-inflammatory properties of the $\alpha$ 7nAChR may have a role
44	in treating CAD.

## 46 Introduction

- 47 Signalling via the alpha7 nicotinic acetylcholine receptor (α7nAChR) can regulate
- 48 inflammation. Following activation of the cholinergic anti-inflammatory pathway, or via
- 49 direct stimulation with agonists, the  $\alpha$ 7nAChR can suppress the release of pro-inflammatory
- 50 cytokines from immune cells<sup>1</sup>. In humans, the  $\alpha$ 7nAChR is expressed both in peripheral
- 51 blood mononuclear cells (PBMCs)<sup>2</sup> and in atherosclerotic plaques<sup>3</sup>. Stimulation of the
- 52  $\alpha$ 7nAChR reduces the inflammatory response in whole blood from healthy donors<sup>4</sup>.
- 53 However, it is unclear whether stimulation of  $\alpha$ 7nAChR can affect the inflammatory response
- 54 in patients with coronary artery disease (CAD). This study aims to investigate the impact of
- 55  $\alpha$ 7nAChR stimulation, using the selective agonist PHA548687, on the immune response in
- 56 PBMCs from both healthy individuals and patients with newly discovered CAD.

### 58 Methods

59 A total of 38 patients with extensive coronary atherosclerosis (CAD) and 38 60 participants with no atherosclerosis (Controls) were recruited from The Swedish CardioPulmonary BioImage Study (SCAPIS)<sup>5</sup>. The study protocol was approved by 61 62 the ethical review board in Gothenburg, Sweden and informed consent was obtained 63 from all participants. Inclusion-criteria for CAD: three or more of the central segments 64 5, 6, 7, 1 or 11 having atherosclerosis or one of these segments with significant 65 stenosis (>50%). When calcium blooming was present, the level of stenosis was set to 66 1-49%. Inclusion-criteria for controls: no signs of coronary atherosclerosis (negative 67 CCTA and CAC scan). Exclusion criteria: History of myocardial infarction and/or 68 angina pectoris or any symptoms of angina pectoris. Pharmacological treatment with 69 statins within last 12 months. Any major surgical procedure or trauma within 4 weeks 70 of the first study visit.

During the first study visit (CAD1), the CAD group met with a study physician, received lifestyle advice, and were recommended lipid-lowering statins to reduce the risk of future cardiovascular events. The CAD group was invited to a second visit (CAD2) six months later while the control group only attended one visit. Blood samples were drawn during the visits for biochemical analysis and PBMC extraction.



82	TNF response > 200 pg/ml and 10 times higher compared to unstimulated controls receiving
83	PBS. PBMC viability after stimulation with PHA568487 was determined using alamarBlue
84	Cell Viability Reagent (Invitrogen, Waltham, MA, USA) according to the manufacturer's
85	protocol. Two doses of PHA568487 (10 $\mu$ M or 100 $\mu$ M) were tested in human PBMCs
86	obtained from healthy volunteers (blood bank Sahlgrenska University Hospital, n=4) and
87	viability was measured after 24 h. No effect on viability was observed (data not shown).
88	Data were tested for normality with Shapiro Wilk's test and statistical methods
89	chosen accordingly. Population characteristics were analysed using one-way ANOVA
90	followed by Sidak's multiple comparison test. Cytokine data was analysed using one-
91	way ANOVA mixed-effect analysis with Geisser-Greenhouse correction, followed by
92	Holm-Sidak's multiple comparison test. A significance level of p<0.05 was used.
93	Differences in sample numbers were due to lack of sample material or lack of LPS
94	response. The statistical analyses were conducted using GraphPad Prism software (La
95	Jolla, USA) and IBM SPSS Statistics (NY, USA).

### 97 **Results**

98 Statin treatment reduced cholesterol and LDL levels in CAD2 (Figure 1A). Among	the thre
---	----------

- 99 groups, only one cytokine, TNF, was significantly reduced (Figure 1B-D). In Controls the
- 100 α7nAChR agonist PHA568487 reduced TNF levels while IL-6 levels were increased (Figure
- 101 1B). In CAD1, PHA568487 reduced the concentration of 12 out of the 17 cytokines analyzed
- 102 (Figure 1C) whereas in CAD2, only TNF was reduced after PHA568487 treatment (Figure 1D).
- 103 When dividing the CAD2 group into the two treatment categories, statin and lifestyle advice
- 104 (n=20) versus lifestyle advice only (n=9), PHA568487 decreased the concentration of five
- 105 cytokines in PBMCs from patients receiving lifestyle advice only (Fig. 1E). The LPS response
- 106 was similar in Controls, CAD1 and CAD2. Likewise, there was no difference when
- 107 comparing the LPS response of patients receiving lipid-lowering treatment and lifestyle
- 108 advice to those receiving lifestyle advice only.

# 110 **Discussion**

111	To the best of our knowledge, this is the first study to demonstrate a significant anti-
112	inflammatory effect of $\alpha$ 7nAChR stimulation on PBMCs from patients with newly
113	discovered CAD. The study also confirms previous anti-inflammatory effects of $\alpha$ 7nAChR
114	stimulation in whole blood from healthy controls <sup>4</sup> . Interestingly, after six months of statin
115	treatment, the anti-inflammatory effect of $\alpha$ 7nAChR stimulation was reduced. Furthermore,
116	patients receiving lifestyle advice had a greater anti-inflammatory effect of PHA56847
117	compared to patients receiving statins and lifestyle advice. These findings implicate that
118	statins influence the inflammatory response. Indeed, statins not only reduce LDL levels in
119	patients, but also inflammation by lowering the inflammatory biomarker hsCRP <sup>6</sup> .
120	Furthermore, statins can suppress cytokine secretion from PBMCs; in hyperlipidemic
121	patients, simvastatin treatment reduced secretion of IL-1 $\beta$ from PBMCs <sup>7</sup> . Intriguingly, the
122	effect of $\alpha$ 7nAChR stimulation is diminished after statin treatment. This lack of effect may be
123	due to shared signaling pathways between the two, as both statins $^8$ and $\alpha7nAChR$ agonists $^9$
124	have been suggested to exert their anti-inflammatory effects by reducing the activity of the
125	transcription factor nuclear factor- $\kappa$ B. Another possibility is that statins could alter the
126	expression level of $\alpha$ 7nAChR <sup>9</sup> . Surprisingly, IL-6 was increased in Controls, which may be
127	explained by the fact that IL-6 is a pleiotropic cytokine that can both increase and reduce
128	inflammation <sup>10</sup> . A limitation of the current study is that some participants were excluded due
129	to low cell numbers from PBMC isolation or lack of LPS response, which prevented us from
130	conducting a paired t-test analysis. Despite this limitation, the number of participants in each
131	group was sufficient to identify significant differences.
132	In conclusion, stimulation of $\alpha$ 7nAChR with PHA568487 reduces the inflammatory
133	response of human PBMCs. This effect is more prominent in PBMCs from patients with

134	newly discovered CA	D, demonstrating the potential of $\alpha$ 7nAChR's anti-inflamm	natory
		· · · · · · · · · · · · · · · · · · ·	

- 135 properties in treating chronic inflammatory diseases such as CAD.
- 136

### 137 Funding

- 138 This work was supported by the Swedish Research Council, the Swedish Heart-Lung
- 139 Foundation, Mary von Sydow foundation, Stiftelsen Gamla tjänarinnor, Stiftelsen Tornspiran,
- 140 Dr. Felix Neuberghs Foundation, Wilhelm and Martina Lundgren foundation and Grants
- 141 from the Swedish state under the agreement between the Swedish government and the county
- 142 councils, the ALF-agreement (ALF GBG-723131).
- 143

144 <b>Discl</b> o	osures
--------------------	--------

- 145 None
- 146

### 147 Data availability

- 148 The participant-level datasets used for this report have been deposited with the Swedish
- 149 National Data Service (https://snd.gu.se/, a data repository certified by Core Trust Seal). Due
- 150 to patient consent and confidentiality agreements, the datasets can be made available for
- 151 validation purposes by contacting snd@snd.gu.se. Data access will be evaluated according to
- 152 Swedish legislation. Data access for research related questions in the program can be made
- available by contacting the corresponding author.

154

#### 155 **Figure Legend**

156 Figure 1. Stimulation of the alpha7 nicotinic acetylcholine receptor (a7nAChR) decreases

157 the inflammatory response in PBMCs from patients with newly discovered coronary artery

158	disease. PBMCs were c	hallenged with LPS	(8.33 ng/ml) and	d co-treated with o	7nAChR agonist

- 159 PHA-568487 (83 µM) for 4 hours. (A) Population characteristics. First panel from left;
- 160 distribution of women and men included in the study, numbers above bars shows exact numbers
- 161 of participants, second panel from left; age, weight (kg) and body mass index (BMI, kg/m<sup>2</sup>), third
- 162 panel from left; systolic and diastolic blood pressure (SBP, DBP), fourth panel from left; glucose
- 163 (Glu), HbA1c, LDL and HDL (all in mmol/L), fifth panel from left C-reactive protein (CRP,
- 164 mg/L) and white blood cell (WBC,  $10^{9}$ /L). Data expressed as mean ± SD. (B-E) Multiplex
- 165 analysis of cytokines IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p70), IL-13, IL-17A,
- 166 G-CSF, GM-CSF, IFNγ, MCP-1, MIP-1β and TNF in (B) Controls (n=25-26), (C) CAD visit 1
- 167 (CAD1, n=19-21), (D) CAD visit 2 (CAD2, n=28-29) and (E) CAD visit 2 showing PBMC
- 168 response from patients who only received life-style advice (CAD2-LS, n=9). Cytokine data
- 169 expressed as mean  $\pm$  SEM. Shaded areas highlights cytokines significantly decreased by
- 170  $\alpha$ 7nAChR agonist PHA568487. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001.
- 171
- 172
- 173
- 174

### 175 **References**

176 de Jonge WJ, Ulloa L. The alpha7 nicotinic acetylcholine receptor as a 1. 177 pharmacological target for inflammation. Br J Pharmacol. 2007;151(7):915-29. 178 2. Pattanaik B, Hammarlund M, Mjörnstedt F, Ulleryd MA, Zhong W, Uhlén M, et al. 179 Polymorphisms in alpha 7 nicotinic acetylcholine receptor gene, CHRNA7, and its partially 180 duplicated gene, CHRFAM7A, associate with increased inflammatory response in human 181 peripheral mononuclear cells. FASEB journal : official publication of the Federation of 182 American Societies for Experimental Biology. 2022;36(5):e22271. 183 Johansson ME, Ulleryd MA, Bernardi A, Lundberg AM, Andersson A, Folkersen L, 3. 184 et al. α7 Nicotinic acetylcholine receptor is expressed in human atherosclerosis and inhibits 185 disease in mice--brief report. Arteriosclerosis, thrombosis, and vascular biology. 186 2014;34(12):2632-6. 187 Ulleryd MA, Mjornstedt F, Panagaki D, Yang LJ, Engevall K, Gutierrez S, et al. 4. 188 Stimulation of alpha 7 nicotinic acetylcholine receptor (alpha7nAChR) inhibits 189 atherosclerosis via immunomodulatory effects on myeloid cells. Atherosclerosis. 190 2019;287:122-33. 191 5. Bergström G, Persson M, Adiels M, Björnson E, Bonander C, Ahlström H, et al. 192 Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population. 193 Circulation. 2021;144(12):916-29. 194 Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. 6. 195 Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after 196 initiation of rosuvastatin: a prospective study of the JUPITER trial. The Lancet. 197 2009;**373(9670)**:1175-82. 198 7. Boland AJ, Gangadharan N, Kavanagh P, Hemeryck L, Kieran J, Barry M, et al. 199 Simvastatin Suppresses Interleukin Iß Release in Human Peripheral Blood Mononuclear 200 Cells Stimulated With Cholesterol Crystals. Journal of Cardiovascular Pharmacology and 201 Therapeutics. 2018;23(6):509-17. 202 Ortego M, Bustos C, Hernández-Presa MA, Tuñón J, Díaz C, Hernández G, Egido J. 8. 203 Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth 204 muscle cells and mononuclear cells. Atherosclerosis. 1999;147(2):253-61. 205 9. Xu H, Shi Q, Mo Y, Wu L, Gu J, Xu Y. Downregulation of  $\alpha$ 7 nicotinic acetylcholine 206 receptors in peripheral blood monocytes is associated with enhanced inflammation in 207 preeclampsia. BMC Pregnancy and Childbirth. 2019;19(1). 208 10. Reeh H, Rudolph N, Billing U, Christen H, Streif S, Bullinger E, et al. Response to 209 IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor  $\alpha$  to 210 gp130 expression: fusing experimental insights and dynamic modelling. *Cell Commun* 211 Signal. 2019;17(1):46. 212



Graphical Abstract created with BioRender.com

